In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
In the latest session, PTC Therapeutics Inc (NASDAQ: PTCT) closed at $49.59 down -0.42% from its previous closing price of $49.8. In other words, the price has decreased by -$0.42 from its previous closing price. On the day, 3.24 million shares were traded. PTCT stock price reached its highest trading level at $54.24 during the session, while it also had its lowest trading level at $48.97.
Ratios:
For a deeper understanding of PTC Therapeutics Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 1.98 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 5.65. For the most recent quarter (mrq), Quick Ratio is recorded 3.57 and its Current Ratio is at 3.62.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Truist on June 17, 2025, initiated with a Buy rating and assigned the stock a target price of $80.
On May 09, 2025, BofA Securities Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $68.
Citigroup Upgraded its Sell to Neutral on May 07, 2025, while the target price for the stock was maintained at $40.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 15 ’25 when Boulding Mark Elliott sold 2,813 shares for $48.58 per share. The transaction valued at 136,656 led to the insider holds 103,901 shares of the business.
Boulding Mark Elliott bought 2,813 shares of PTCT for $136,646 on Aug 15 ’25. On Aug 05 ’25, another insider, Klein Matthew B., who serves as the CHIEF EXECUTIVE OFFICER of the company, sold 10,739 shares for $51.74 each. As a result, the insider received 555,636 and left with 337,767 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PTCT now has a Market Capitalization of 3939335168 and an Enterprise Value of 4440357888. As of this moment, PTC’s Price-to-Earnings (P/E) ratio for their current fiscal year is 7.11. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.15. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.23. Its current Enterprise Value per Revenue stands at 2.516 whereas that against EBITDA is 4.962.
Stock Price History:
The Beta on a monthly basis for PTCT is 0.53, which has changed by 0.46153843 over the last 52 weeks, in comparison to a change of 0.14064062 over the same period for the S&P500. Over the past 52 weeks, PTCT has reached a high of $58.38, while it has fallen to a 52-week low of $30.41. The 50-Day Moving Average of the stock is 1.11%, while the 200-Day Moving Average is calculated to be 3.73%.
Shares Statistics:
For the past three months, PTCT has traded an average of 1.13M shares per day and 1618560 over the past ten days. A total of 79.38M shares are outstanding, with a floating share count of 76.03M. Insiders hold about 4.29% of the company’s shares, while institutions hold 100.00% stake in the company. Shares short for PTCT as of 1753920000 were 6016226 with a Short Ratio of 5.33, compared to 1751241600 on 5996119. Therefore, it implies a Short% of Shares Outstanding of 6016226 and a Short% of Float of 8.709999999999999.
Earnings Estimates
As of right now, 5.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is -$0.84, with high estimates of -$0.05 and low estimates of -$1.25.
Analysts are recommending an EPS of between $8.97 and $7.53 for the fiscal current year, implying an average EPS of $8.27. EPS for the following year is -$1.72, with 6.0 analysts recommending between -$0.35 and -$3.3.
Revenue Estimates
A total of 12 analysts believe the company’s revenue will be $187.58M this quarter.It ranges from a high estimate of $314.85M to a low estimate of $140.3M. As of the current estimate, PTC Therapeutics Inc’s year-ago sales were $196.79MFor the next quarter, 12 analysts are estimating revenue of $203.43M. There is a high estimate of $276.55M for the next quarter, whereas the lowest estimate is $147.93M.
A total of 16 analysts have provided revenue estimates for PTCT’s current fiscal year. The highest revenue estimate was $1.85B, while the lowest revenue estimate was $1.65B, resulting in an average revenue estimate of $1.74B. In the same quarter a year ago, actual revenue was $806.78MBased on 16 analysts’ estimates, the company’s revenue will be $867M in the next fiscal year. The high estimate is $1.12B and the low estimate is $531.9M.
